-
A Clinical Study to Evaluate the Safety and Efficacy of ETX101 in Infants and Children With SCN1A-Positive Dravet Syndrome
NCT05419492 ·
Phase: Phase 1, Phase 2 ·
Ages: 6 Months to 17 Years ·
Sex: All (male and female)
· North Carolina: Durham
-
A Double-blind Study Evaluating the Efficacy, Safety, and Tolerability of Zorevunersen in Patients With Dravet Syndrome
NCT06872125 ·
Phase: Phase 3 ·
Ages: 2 Years to 17 Years ·
Sex: All (male and female)
· North Carolina: Chapel Hill, Durham
-
A Phase 1/2 Study of NRTX-1001 Neuronal Cell Therapy in Drug-Resistant Bilateral Mesial Temporal Lobe Epilepsy (MTLE)
NCT06422923 ·
Phase: Phase 1, Phase 2 ·
Ages: 18 Years to 75 Years ·
Sex: All (male and female)
· North Carolina: Charlotte, Durham, Winston-Salem
-
A Randomized Study of XEN1101 Versus Placebo in Focal-Onset Seizures (X-TOLE3)
NCT05716100 ·
Phase: Phase 3 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· North Carolina: Durham
-
A Study of EPX-100 (Clemizole Hydrochloride) in Participants With Dravet Syndrome
NCT04462770 ·
Phase: Phase 3 ·
Ages: 2 Years and older ·
Sex: All (male and female)
· North Carolina: Durham, Morrisville, Winston-Salem
-
A Study to Determine if BHV-7000 is Effective and Safe in Adults With Refractory Focal Onset Epilepsy
NCT06132893 ·
Phase: Phase 2, Phase 3 ·
Ages: 18 Years to 75 Years ·
Sex: All (male and female)
· North Carolina: Charlotte, Mooresville, Winston-Salem
-
A Study to Evaluate XEN1101 as Adjunctive Therapy in Primary Generalized Tonic-Clonic Seizures
NCT05667142 ·
Phase: Phase 3 ·
Ages: 12 Years and older ·
Sex: All (male and female)
· North Carolina: Charlotte, Durham, Winston-Salem
-
A Study to Test the Safety and Tolerability of Brivaracetam in Children and Adolescents With Seizures
NCT04715646 ·
Phase: Phase 3 ·
Ages: 1 Month and older ·
Sex: All (male and female)
· North Carolina: Durham
-
ASCEND: Safety and Tolerability of ION337 for the Treatment of Dravet Syndrome
NCT07531745 ·
Phase: Phase 1, Phase 2 ·
Ages: 2 Years to 12 Years ·
Sex: All (male and female)
· North Carolina: Durham
-
An Efficacy and Safety Study of Clemizole HCl in Patients With Lennox-Gastaut Syndrome
NCT05066217 ·
Phase: Phase 3 ·
Ages: 2 Years to 55 Years ·
Sex: All (male and female)
· North Carolina: Charlotte, Durham, Morrisville
-
B6 Administration for Levetiracetam-Associated Neurobehavioral Changes and Epilepsy
NCT07271966 ·
Phase: Not applicable (e.g. observational or device study) ·
Ages: 18 Years and older ·
Sex: All (male and female)
· North Carolina: Durham
-
Collaborative Care for Anxiety and Depression in Epilepsy
NCT05559749 ·
Phase: Not applicable (e.g. observational or device study) ·
Ages: 18 Years and older ·
Sex: All (male and female)
· North Carolina: Winston-Salem
-
Diagnosing Epilepsy To EffeCT Change
NCT07110337 ·
Phase: Not applicable (e.g. observational or device study) ·
Ages: 18 Years to 75 Years ·
Sex: All (male and female)
· North Carolina: Charlotte, Durham
-
Diagnosing Epilepsy To EffeCT Change Long-Term Follow-Up
NCT07110454 ·
Phase: Not specified ·
Ages: 18 Years to 75 Years ·
Sex: All (male and female)
· North Carolina: Charlotte, Durham
-
Dose Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics And Pharmacodynamics of SIF001 in Healthy Subjects and in Epilepsy Patients
NCT07051629 ·
Phase: Phase 1 ·
Ages: 18 Years to 70 Years ·
Sex: All (male and female)
· North Carolina: Charlotte
-
Investigate Efficacy and Safety of Carisbamate as Adjunctive Treatment for Seizures Associated With LGS in Children and Adults
NCT05219617 ·
Phase: Phase 3 ·
Ages: 4 Years to 55 Years ·
Sex: All (male and female)
· North Carolina: Durham, Winston-Salem
-
Lemborexant Treatment of Insomnia Linked to Epilepsy
NCT06262594 ·
Phase: Phase 3 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· North Carolina: Durham
-
Links Between Epileptic Activity, Sleep Disruption and Mental Content During Sleep
NCT07605858 ·
Phase: Not specified ·
Ages: 18 Years to 55 Years ·
Sex: All (male and female)
· North Carolina: Durham
-
Sleep-Sensitive Seizure Risk Assessment With Wearable EEGs
NCT06545643 ·
Phase: Not applicable (e.g. observational or device study) ·
Ages: 18 Years and older ·
Sex: All (male and female)
· North Carolina: Durham
-
Stopping TSC Onset and Progression 2B: Sirolimus TSC Epilepsy Prevention Study
NCT05104983 ·
Phase: Phase 2 ·
Ages: 1 Day to 6 Months ·
Sex: All (male and female)
· North Carolina: Chapel Hill
-
Study Evaluating the Efficacy and Safety of RAP-219 in Adult Participants With Focal Seizures
NCT07594119 ·
Phase: Phase 3 ·
Ages: 18 Years to 75 Years ·
Sex: All (male and female)
· North Carolina: Raleigh
-
Study Evaluating the Efficacy and Safety of RAP-219 in Adult Participants With Focal Seizures FOCUS-1
NCT07563881 ·
Phase: Phase 3 ·
Ages: 18 Years to 75 Years ·
Sex: All (male and female)
· North Carolina: Asheville
-
Study of NRTX-1001 Neural Cell Therapy in Drug-Resistant Unilateral Mesial Temporal Lobe Epilepsy (EPIC (EPIlepsy Cell Therapy))
NCT05135091 ·
Phase: Phase 3 ·
Ages: 18 Years to 75 Years ·
Sex: All (male and female)
· North Carolina: Charlotte, Durham, Winston-Salem